AMRN ANDA Litigation - Recent Updates re: Generics
This presentation and video for paid subscribers only, provide an update related to recent press releases from AMRN and generic companies, and whether they affect AMRN's ability to keep generics out of the Vascepa market. Plus, I discuss the upcoming events calendar, especially a key event that is likely to occur in July, that is not known to many investors.
VIDEO PROCESSING - TO BE ADDED
May 22, 2020 Hikma Press Release re: ANDA approval by FDA
June 1, 2020 - AMRN press release on relaunch of Vascepa education and promotion - https://investor.amarincorp.com/news-releases/news-release-details/amarin-plans-increase-vascepar-icosapent-ethyl-promotion-and
Info about "authorized generics"
https://www.managedhealthcareexecutive.com/news/what-are-authorized-generics
Disclaimer:
*Emanuel "Manny" Vacchiano, J.D., PhD., is a licensed U.S. patent attorney.
No attorney-client relationship is established by your purchase of this product. If you would like to inquire about a possible legal representation by Dr. Vacchiano and his law firm, Double Helix Law, LLC, please contact Dr. Vacchiano at mannyv@doublehelixlaw.com.
You are reminded as indicated in our terms, that in exchange for getting this analysis at a very reasonable price you agree not to share it with others.
Information provided on ampbiotechresearch.com and by Manny Vacchiano, Amp Biotech Research, LLC, or any of its consultants on the Amp web site and in any of our reports, products and services are for information only and are not investment or legal advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.
#AMRN #Vascepa #triglycerides #cardiovascular #ANDA #patents